Pàgina inicial > Resultats de la cerca: Iida, S.
  Consells de cerca
Cerca simple
Cerca col·leccions:
Ordena'ls per: Mostrar els resultats: Format de visualizació:
Dipòsit Digital de Documents de la UAB 2 registres trobats  La cerca s'ha fet en 0.00 segons. 
1.
13 p, 861.9 KB Ixazomib as postinduction maintenance for patients with newly diagnosed multiple myeloma not undergoing autologous stem cell transplantation : The phase III TOURMALINE-MM4 trial / Dimopoulos, Meletios (The National and Kapodistrian University of Athens) ; Špička, I. (Charles University. Faculty of Medicine in Hradec Králové) ; Quach, H. (St Vincent's Hospital (Sydney)) ; Oriol, Albert (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Hájek, R. (Department of Hemato-oncology. University Hospital Ostrava. University of Ostrava. Faculty of Medicine) ; Garg, M. (Leicester General Hospital (Leicester, Regne Unit)) ; Beksac, M. (Department of Hematology. Ankara University) ; Bringhen, S. (Division of Hematology. University of Torino. Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino) ; Katodritou, E. (Department of Hematology. Theagenion Cancer Hospital) ; Chng, W. J. (Department of Hematology-Oncology. National University Cancer Institute. National University Health System. Yong Loo Lin School of Medicine. Cancer Science Institute of Singapore. National University of Singapore) ; Leleu, Xavier (Pôle Régional de Cancérologie. Department of Haematology. Centre Hospitalier Universitaire La Milétrie-Poitiers) ; Iida, S. (Department of Hematology and Oncology. Nagoya City University. Graduate School of Medical Sciences) ; Mateos, M. V. (Hospital Universitario de Salamanca. Centro de Investigación del Cáncer) ; Morgan, G. (Perlmutter Cancer Center. NYU Langone Health) ; Vorog, A. (Millennium Pharmaceuticals. Inc.. Takeda Pharmaceutical Company Limited) ; Labotka, R. (Millennium Pharmaceuticals. Inc.. Takeda Pharmaceutical Company Limited) ; Wang, B. (Millennium Pharmaceuticals. Inc.. Takeda Pharmaceutical Company Limited) ; Palumbo, A. (Millennium Pharmaceuticals. Inc.. Takeda Pharmaceutical Company Limited) ; Lonial, S. (Department of Hematology and Medical Oncology. Winship Cancer Institute of Emory University) ; Universitat Autònoma de Barcelona
PURPOSE Maintenance therapy prolongs progression-free survival (PFS) in patients with newly diagnosed multiple myeloma (NDMM) not undergoing autologous stem cell transplantation (ASCT) but has generally been limited to immunomodulatory agents. [...]
2020 - 10.1200/JCO.20.02060
Journal of Clinical Oncology, Vol. 38 Núm. 34 (january 2020) , p. 4030-4041  
Registre complet - Creative Commons
2.
10 p, 667.7 KB Daratumumab, lenalidomide, and dexamethasone in relapsed/refractory myeloma : a cytogenetic subgroup analysis of POLLUX / Kaufman, J. L. (Winship Cancer Institute. Emory University) ; Dimopoulos, Meletios (The National and Kapodistrian University of Athens) ; White, D. (Dalhousie University and Queen Elizabeth II Health Sciences Centre) ; Benboubker, L. (Service d'Hématologie et Thérapie Cellulaire. Hôpital Bretonneau. Centre Hospitalier Régional Universitaire) ; Cook, G. (St James's Institute of Oncology. Leeds Teaching Hospitals National Health Service Trust and University of Leeds) ; Leiba, M. (Assuta Ashdod University Hospital. Faculty of Health Science Ben-Gurion University of the Negev) ; Morton, J. (Icon Cancer Care) ; Joy Ho, P. (Institute of Haematology. Royal Prince Alfred Hospital) ; Kim, K. (Department of Medicine. Samsung Medical Center. Sungkyunkwan University School of Medicine) ; Takezako, N. (Department of Hematology. National Hospital Organization Disaster Medical Center of Japan) ; Moreau, Philippe (Hematology. University Hospital Hôtel-Dieu) ; Sutherland, H. J. (Leukemia/Bone Marrow Transplant Program. University of British Columbia) ; Magen, H. (Department of Hematology Chaim Sheba Medical Center. Ramat-Gan. Sackler Faculty of Medicine. Tel Aviv University) ; Iida, S. (Department of Hematology and Oncology. Nagoya City University Graduate School of Medical Sciences) ; Kim, J. S. (Yonsei University College of Medicine. Severance Hospital) ; Miles Prince, H. (Cabrini Hospital. Epworth HealthCare and Sir Peter MacCallum Department of Oncology. University of Melbourne) ; Cochrane, T. (Gold Coast University Hospital and Griffiths University) ; Oriol, Albert (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Bahlis, N. J. (University of Calgary. Arnie Charbonneau Cancer Institute) ; Chari, Ajai (Icahn School of Medicine at Mount Sinai) ; O'Rourke, L. (Janssen Research & Development) ; Trivedi, S. (Janssen Research & Development) ; Casneuf, T. (Janssen Research & Development) ; Krevvata, M. (Janssen Research & Development) ; Ukropec, J. (Janssen Global Medical Affairs) ; Kobos, R. (Janssen Research & Development) ; Avet-Loiseau, Hervé (Unite de Genomique du Myelome. IUC-Oncopole) ; Usmani, S. Z. (Levine Cancer Institute/Atrium Health) ; San-Miguel, J. (Clínica Universidad de Navarra. Centro de Investigación Médica Aplicada) ; Universitat Autònoma de Barcelona
High cytogenetic risk abnormalities confer poor outcomes in multiple myeloma patients. In POLLUX, daratumumab/lenalidomide/dexamethasone (D-Rd) demonstrated significant clinical benefit versus lenalidomide/dexamethasone (Rd) in relapsed/refractory multiple myeloma (RRMM) patients. [...]
2020 - 10.1038/s41408-020-00375-2
Blood Cancer Journal, Vol. 10 Núm. 11 (january 2020) , p. 111  
Registre complet - Creative Commons

Us interessa rebre alertes sobre nous resultats d'aquesta cerca?
Definiu una alerta personal via correu electrònic o subscribiu-vos al canal RSS.
Dipòsit Digital de Documents de la UAB :: Cerca :: Lliura :: Personalitza :: Ajuda
Powered by Invenio v1.1.6
Mantingut per ddd.bib@uab.cat  :: Metadades subjectes a:
Col·laborem